Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Anaptysbio Inc (NQ: ANAB ) 33.70 -0.75 (-2.18%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Anaptysbio Inc < Previous 1 2 Next > Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties May 09, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 11, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting February 29, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference January 31, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals November 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Named a BioSpace 2024 Best Places to Work Winner November 07, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Participation in November Investor Conferences November 01, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress October 11, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 October 09, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) October 09, 2023 From AnaptysBio, Inc. Via GlobeNewswire Argenx's 28% Surge & Promising Product Propel Investor Confidence September 25, 2023 Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. Via MarketBeat AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors September 18, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit September 12, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update August 07, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer July 31, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces Participation in Upcoming Investor Conferences May 30, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update May 11, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP) May 02, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors April 06, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent March 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 01, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference February 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces Stock Repurchase Plan January 13, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies January 05, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer December 02, 2022 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference November 21, 2022 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio to Participate in Upcoming November Investor Conferences November 09, 2022 From AnaptysBio, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.